Determining disparities in treatment of pulmonary arterial hypertension nationally
确定全国肺动脉高压治疗的差异
基本信息
- 批准号:10017704
- 负责人:
- 金额:$ 8.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:Action ResearchAddressAffectAgeAlgorithmsAmericanAwardBostonCardiac Catheterization ProceduresCardiopulmonaryCaringChestClinicalCodeCohort StudiesCollectionCommunitiesCommunity PracticeDataDevelopmentDiagnosisDiagnosticDiagnostic ProcedureDiagnostic testsDiseaseDisease SurveillanceEarly DiagnosisEconomicsEnsureEnvironmentEventExclusionFoundationsGoalsGoldGrantGuidelinesHealth ServicesHealthcareHealthcare SystemsICD-9InequalityIntegrated Delivery of Health CareIntegrated Health Care SystemsInternational Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)K-Series Research Career ProgramsLungMedical centerMentorsModelingMorbidity - disease rateNeighborhood Health CenterOutcomePatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacy facilityPopulationPublishingPulmonary Heart DiseasePulmonary HypertensionRecommendationResearchResearch PersonnelResearch Project GrantsResearch ProposalsSeriesSeverity of illnessSocietiesSocioeconomic StatusSpecificitySubgroupSymptomsSystemTrainingValidationVasodilator AgentsVeteransWorkbasebiomedical referral centercare deliverycareercohortcomorbiditydata registrydata resourcedemographicsdiagnostic accuracydisparity reductionethnic minority populationhealth administrationhealth care deliveryhealth care disparityhealth care service utilizationhealth disparityhypertension controlhypertension treatmentimprovedimproved outcomeinsightlow socioeconomic statuspulmonary arterial hypertensionracial and ethnicruralityskillssocioeconomicssoundsystematic reviewtargeted treatmenttooltreatment as usualtreatment disparity
项目摘要
PROJECT SUMMARY/ABSTRACT
Pulmonary arterial hypertension (PAH) is a severe disease of the pulmonary vasculature characterized by high
symptom burden, significant healthcare utilization, and poor survival. Recently developed targeted therapies
have improved outcomes for patients with PAH; however, the disease remains significantly underrecognized and
undertreated when patients are managed outside of PAH referral centers. Despite the importance of early
diagnosis and initiation of treatment in altering the disease trajectory, little is known about the influences on PAH
care on a population level including potential patient-, environment-, or system-level determinants of treatment
for PAH. Single-center studies suggest that disparities in PAH outcomes may exist among different racial/ethnic
or socioeconomic status groups, though the factors that account for these differences such as disparities in
treatment rates among these populations remain to be determined. Expanding our understanding of PAH care
beyond PAH registry data and single-center cohort studies is essential to close care gaps on a population level.
Administrative data that captures care within a national, diverse, integrated health system such as the Veteran’s
Health Administration (VA) can serve as an important tool to improve our understanding of the delivery of PAH
care in usual community practice and to detect health disparities in PAH. To capitalize on this rich data resource
for this purpose, we must first establish sound mechanisms to identify PAH in administrative data, mechanisms
that are currently lacking in this field. I propose two foundational steps to enhance our understanding of the
drivers of PAH care delivery in the community and to fill currently unmet needs in PAH research: 1) create and
validate algorithms to differentiate PAH from other, more common forms of pulmonary hypertension in
administrative data and 2) identify patient- and facility-level determinants of treatment for PAH. Completion of
this research proposal will advance the field of PAH by generating a collection of validated tools that other PAH
researchers can utilize to better address diverse research questions and by revealing drivers of PAH care
delivery on a population level including racial/ethnic and economic disparities in treatment rates. The results of
this study will establish a foundation on which to build and implement effective strategies to improve treatment
rates and mitigate health disparities for patients with PAH. Meanwhile, the skills I gain through this mentored
research project and complementary didactic training will advance my career goal of becoming a leading
independent investigator focused on identifying and addressing cardiopulmonary health disparities.
项目总结/摘要
肺动脉高压(PAH)是一种严重的肺血管疾病,其特征是高血压,
症状负担、显著的医疗保健利用和较差的生存率。最近开发的靶向治疗
改善了PAH患者的结局;然而,该疾病仍然被严重低估,
当患者在PAH转诊中心外接受治疗时,治疗不足。尽管早期的重要性
诊断和开始治疗改变疾病轨迹,对PAH的影响知之甚少
在人群水平上的护理,包括潜在的患者、环境或系统水平的治疗决定因素
PAH。单中心研究表明,不同种族/民族之间可能存在PAH结局差异
或社会经济地位群体,尽管造成这些差异的因素,如
这些人群的治疗率仍有待确定。扩大我们对PAH护理的理解
除了PAH登记数据和单中心队列研究之外,对缩小人群水平的护理差距至关重要。
在国家、多样化、综合的卫生系统(如退伍军人医疗保健系统)中获取护理的管理数据
卫生管理局(VA)可以作为一个重要的工具,以提高我们对PAH的交付的理解
在通常的社区实践中进行护理,并检测PAH中的健康差异。为了充分利用这一丰富的数据资源,
为此,我们必须首先建立健全的机制,以确定PAH在行政数据,机制
这是目前这个领域所缺乏的。我提出两个基本步骤,以加强我们对
在社区中提供PAH护理的驱动因素,并满足PAH研究中目前未满足的需求:1)创建和
验证区分PAH与其他更常见形式的肺动脉高压的算法,
管理数据和2)确定PAH治疗的患者和机构水平决定因素。完成
这项研究提案将通过产生一系列经过验证的工具来推进PAH领域,
研究人员可以更好地解决各种研究问题,并通过揭示PAH护理的驱动因素,
在人口水平上提供服务,包括治疗率方面的种族/族裔和经济差异。的结果
这项研究将为建立和实施有效的策略以改善治疗奠定基础
降低PAH患者的发病率并减轻健康差异。与此同时,我通过此获得的技能得到了指导
研究项目和补充教学培训将推动我成为一个领先的职业目标
独立调查员专注于识别和解决心肺健康差异。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kari Gillmeyer其他文献
Kari Gillmeyer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 8.04万 - 项目类别:
Research Grant